{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:23:36Z","timestamp":1794561816611,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Harry R. and Angeline E. Quadracci Professor in Parkinson\u2019s Research Endowment"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Glycolytic and mitochondrial oxidative metabolism, which are two major energy sources in tumors, are potential targets in cancer treatment. Metabolic reprogramming from glycolysis to mitochondrial oxidative metabolism and vice versa is an adaptive strategy with which tumor cells obtain energy to survive and thrive under the compromised conditions of glycolysis and mitochondrial respiration. Developing highly potent, nontoxic, and tumor-selective oxidative phosphorylation (OXPHOS) inhibitors may help advance therapeutic targeting of mitochondrial drugs in cancer. The FDA-approved antimalarial drug atovaquone (ATO), a mitochondrial complex III inhibitor, was repurposed in cancer treatment. Here, we developed a new class of PEGylated mitochondria-targeted ATO (Mito-(PEG)n-ATO). Depending on the PEGylation chain length (n), Mito-PEG-ATO analogs inhibit both mitochondrial complex I- and complex III-induced oxygen consumption in human pancreatic (MiaPaCa-2) and brain (U87MG) cancer cells. Mito-PEG<jats:sub>5<\/jats:sub>-ATO is one of the most potent antiproliferative mitochondria-targeted compounds (IC<jats:sub>50<\/jats:sub>\u2009=\u200938\u00a0nM) in MiaPaCa-2 cells, and is more effective than other inhibitors of OXPHOS in MiaPaCa-2 and U87MG cells. Furthermore, we show that the combined use of the most potent OXPHOS-targeted inhibitors (Mito-PEG<jats:sub>5<\/jats:sub>-ATO) and inhibitors of monocarboxylate transporters (MCT-1 and MCT-4), Krebs cycle redox metabolism, or glutaminolysis will synergistically abrogate tumor cell proliferation. Potential clinical benefits of these combinatorial therapies are discussed.<\/jats:p>","DOI":"10.1038\/s41598-022-08984-6","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T15:56:58Z","timestamp":1648223818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation"],"prefix":"10.1038","volume":"12","author":[{"given":"Gang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micael","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaraman","family":"Kalyanaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"issue":"6487","key":"8984_CR1","doi-asserted-by":"publisher","first-page":"10047","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert, B., Solmonson, A. & De Berardinis, R. J. Metabolic reprogramming and cancer progression. Science 368(6487), 10047 (2020).","journal-title":"Science"},{"issue":"10","key":"8984_CR2","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-11-3928","volume":"72","author":"G Cheng","year":"2012","unstructured":"Cheng, G. et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 72(10), 2634\u20132644 (2012).","journal-title":"Cancer Res."},{"issue":"13","key":"8984_CR3","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1158\/0008-5472.CAN-15-2534","volume":"76","author":"G Cheng","year":"2016","unstructured":"Cheng, G. et al. Mitochondria-targeted analogues of metformin exhibit enhanced antiproliferative and radiosensitizing effects in pancreatic cancer cells. Cancer Res. 76(13), 3904\u20133915 (2016).","journal-title":"Cancer Res."},{"issue":"2","key":"8984_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez, L. E. et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 71(2), 523\u201330 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"8984_CR5","unstructured":"Canadian Cancer Trials Group, National Cancer Institute (NCI), International Breast Cancer Study Group, ICR-CTSU, A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer (2010). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01101438."},{"key":"8984_CR6","unstructured":"M.D. Anderson Cancer Center, IACS-010759 in Advanced Cancers (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03291938."},{"key":"8984_CR7","unstructured":"Baylor College of Medicine, William Marsh Rice University, Atovaquone (Mepron\u00ae) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) (ATACC AML) (2018). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03568994."},{"key":"8984_CR8","unstructured":"Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Weill Medical College of Cornell University (2017). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03026517."},{"issue":"11","key":"8984_CR9","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"TM Ashton","year":"2018","unstructured":"Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A. & Higgins, G. S. Oxidative phosphorylation as an emerging target in cancer therapy. Clin. Cancer Res. 24(11), 2482\u20132490 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"8984_CR10","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med. 24(7), 1036\u20131046 (2018).","journal-title":"Nat. Med."},{"issue":"3","key":"8984_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cmet.2020.06.019","volume":"32","author":"K Vasan","year":"2020","unstructured":"Vasan, K., Werner, M. & Chandel, N. S. Mitochondrial metabolism as a target for cancer therapy. Cell Metab 32(3), 341\u2013352 (2020).","journal-title":"Cell Metab"},{"issue":"3","key":"8984_CR12","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/0008-5472.CAN-13-2034","volume":"74","author":"JR Doherty","year":"2014","unstructured":"Doherty, J. R. et al. Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. Cancer Res. 74(3), 908\u2013920 (2014).","journal-title":"Cancer Res."},{"issue":"1\u20132","key":"8984_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/jnr.20294","volume":"79","author":"L Hertz","year":"2005","unstructured":"Hertz, L. & Dienel, G. A. Lactate transport and transporters: general principles and functional roles in brain cells. J. Neurosci. Res. 79(1\u20132), 11\u201318 (2005).","journal-title":"J. Neurosci. Res."},{"key":"8984_CR14","unstructured":"Cancer Research UK, A Phase I Trial of AZD3965 in Patients With Advanced Cancer (2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01791595."},{"issue":"21","key":"8984_CR15","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-16-2686","volume":"77","author":"M Beloueche-Babari","year":"2017","unstructured":"Beloueche-Babari, M. et al. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res. 77(21), 5913\u20135924 (2017).","journal-title":"Cancer Res."},{"issue":"7","key":"8984_CR16","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3324\/haematol.2016.163030","volume":"102","author":"RA Noble","year":"2017","unstructured":"Noble, R. A. et al. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 102(7), 1247\u20131257 (2017).","journal-title":"Haematologica"},{"issue":"4","key":"8984_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross, M. I. et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13(4), 890\u2013901 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"8984_CR18","unstructured":"N. Tucker, FDA Grants Fast Track Designation to CPI-613 in Metastatic Pancreatic Cancer (2020). https:\/\/www.targetedonc.com\/view\/fda-grants-fast-track-designation-to-cpi-613-in-metastatic-pancreatic-cancer."},{"issue":"1","key":"8984_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2049-3002-2-4","volume":"2","author":"SD Stuart","year":"2014","unstructured":"Stuart, S. D. et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2(1), 4 (2014).","journal-title":"Cancer Metab."},{"key":"8984_CR20","unstructured":"Wake Forest University Health Sciences, CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (2021). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01835041."},{"key":"8984_CR21","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.7554\/eLife.56749","volume":"9","author":"H Jin","year":"2020","unstructured":"Jin, H. et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife 9, 1008 (2020).","journal-title":"Elife"},{"issue":"5","key":"8984_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/CCO.0000000000000467","volume":"30","author":"R Bajpai","year":"2018","unstructured":"Bajpai, R. & Shanmugam, M. Targeting cancer metabolism through synthetic lethality-based combinatorial treatment strategies. Curr. Opin. Oncol. 30(5), 338\u2013344 (2018).","journal-title":"Curr. Opin. Oncol."},{"issue":"6","key":"8984_CR23","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s11064-017-2212-1","volume":"42","author":"J M\u00e1rquez","year":"2017","unstructured":"M\u00e1rquez, J. et al. Glutamine addiction in gliomas. Neurochem. Res. 42(6), 1735\u20131746 (2017).","journal-title":"Neurochem. Res."},{"issue":"8","key":"8984_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","volume":"35","author":"DR Wise","year":"2010","unstructured":"Wise, D. R. & Thompson, C. B. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem. Sci. 35(8), 427\u2013433 (2010).","journal-title":"Trends Biochem. Sci."},{"key":"8984_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cbpa.2021.01.006","volume":"62","author":"YA Shen","year":"2021","unstructured":"Shen, Y. A. et al. Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment. Curr. Opin. Chem. Biol. 62, 64\u201381 (2021).","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"7","key":"8984_CR26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/0006-2952(92)90213-3","volume":"43","author":"M Fry","year":"1992","unstructured":"Fry, M. & Pudney, M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4\u2019-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol. 43(7), 1545\u20131553 (1992).","journal-title":"Biochem. Pharmacol."},{"issue":"33","key":"8984_CR27","doi-asserted-by":"publisher","first-page":"31312","DOI":"10.1074\/jbc.M304042200","volume":"278","author":"JJ Kessl","year":"2003","unstructured":"Kessl, J. J. et al. Molecular basis for atovaquone binding to the cytochrome bc1 complex. J. Biol. Chem. 278(33), 31312\u201331318 (2003).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"8984_CR28","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1038\/ncomms5029","volume":"5","author":"D Birth","year":"2014","unstructured":"Birth, D., Kao, W.-C. & Hunte, C. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action. Nat. Commun. 5(1), 4029 (2014).","journal-title":"Nat. Commun."},{"issue":"1","key":"8984_CR29","doi-asserted-by":"publisher","first-page":"17872","DOI":"10.1038\/s41598-020-74808-0","volume":"10","author":"G Cheng","year":"2020","unstructured":"Cheng, G. et al. Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone. Sci. Rep. 10(1), 17872 (2020).","journal-title":"Sci. Rep."},{"issue":"4","key":"8984_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1083\/jcb.201511036","volume":"212","author":"P Mishra","year":"2016","unstructured":"Mishra, P. & Chan, D. C. Metabolic regulation of mitochondrial dynamics. J. Cell Biol. 212(4), 379\u2013387 (2016).","journal-title":"J. Cell Biol."},{"issue":"21","key":"8984_CR31","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese, F. M. & Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10(21), 1451\u20131458 (2005).","journal-title":"Drug Discov. Today"},{"issue":"1","key":"8984_CR32","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/s41467-019-10042-1","volume":"10","author":"G Cheng","year":"2019","unstructured":"Cheng, G. et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat. Commun. 10(1), 2205 (2019).","journal-title":"Nat. Commun."},{"issue":"38","key":"8984_CR33","doi-asserted-by":"publisher","first-page":"14891","DOI":"10.1074\/jbc.RA117.001469","volume":"293","author":"KA Boyle","year":"2018","unstructured":"Boyle, K. A. et al. Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. J. Biol. Chem. 293(38), 14891\u201314904 (2018).","journal-title":"J. Biol. Chem."},{"key":"8984_CR34","doi-asserted-by":"publisher","first-page":"e02242","DOI":"10.7554\/eLife.02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 3, e02242 (2014).","journal-title":"Elife"},{"issue":"11","key":"8984_CR35","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1016\/j.celrep.2018.11.043","volume":"25","author":"D Benjamin","year":"2018","unstructured":"Benjamin, D. et al. Dual inhibition of the lactate transporters MCT1 and MCT4 Is synthetic lethal with metformin due to NAD+ depletion in cancer cells. Cell Rep. 25(11), 3047-3058.e4 (2018).","journal-title":"Cell Rep."},{"key":"8984_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.isci.2018.04.013","volume":"3","author":"J Pan","year":"2018","unstructured":"Pan, J. et al. Mitochondria-targeted honokiol confers a striking inhibitory effect on lung cancer via inhibiting complex I activity. iScience 3, 192\u2013207 (2018).","journal-title":"iScience"},{"issue":"3","key":"8984_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.freeradbiomed.2008.10.031","volume":"46","author":"J Zielonka","year":"2009","unstructured":"Zielonka, J., Hardy, M. & Kalyanaraman, B. HPLC study of oxidation products of hydroethidine in chemical and biological systems: Ramifications in superoxide measurements. Free Radic. Biol. Med. 46(3), 329\u2013338 (2009).","journal-title":"Free Radic. Biol. Med."},{"issue":"12","key":"8984_CR38","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrd.2018.174","volume":"17","author":"MP Murphy","year":"2018","unstructured":"Murphy, M. P. & Hartley, R. C. Mitochondria as a therapeutic target for common pathologies. Nat. Rev. Drug Discov. 17(12), 865\u2013886 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"8984_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/d41573-021-00001-1","volume":"20","author":"S Crunkhorn","year":"2021","unstructured":"Crunkhorn, S. Targeting the mitochondria to block tumour growth. Nat. Rev. Drug Discov. 20(2), 97 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"8984_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ab.2017.07.009","volume":"552","author":"LD Zorova","year":"2018","unstructured":"Zorova, L. D. et al. Mitochondrial membrane potential. Anal. Biochem. 552, 50\u201359 (2018).","journal-title":"Anal. Biochem."},{"issue":"15","key":"8984_CR41","doi-asserted-by":"publisher","first-page":"10043","DOI":"10.1021\/acs.chemrev.7b00042","volume":"117","author":"J Zielonka","year":"2017","unstructured":"Zielonka, J. et al. Mitochondria-targeted triphenylphosphonium-based compounds: Syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem. Rev. 117(15), 10043\u201310120 (2017).","journal-title":"Chem. Rev."},{"issue":"7","key":"8984_CR42","first-page":"10048","volume":"32","author":"T Riley","year":"2008","unstructured":"Riley, T. & Riggs-Sauthier, J. The benefits and challenges of PEGylating small molecules. Pharm. Technol. 32(7), 10048 (2008).","journal-title":"Pharm. Technol."},{"issue":"1","key":"8984_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1124\/mol.109.054551","volume":"76","author":"J Li","year":"2009","unstructured":"Li, J. et al. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol. Pharmacol. 76(1), 81\u201390 (2009).","journal-title":"Mol. Pharmacol."},{"issue":"14","key":"8984_CR44","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood-2015-07-660506","volume":"128","author":"M Xiang","year":"2016","unstructured":"Xiang, M. et al. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood 128(14), 1845\u20131853 (2016).","journal-title":"Blood"},{"issue":"2","key":"8984_CR45","doi-asserted-by":"publisher","first-page":"10078","DOI":"10.3390\/pharmaceutics10020060","volume":"10","author":"H Takabe","year":"2018","unstructured":"Takabe, H. et al. A repurposed drug for brain cancer: Enhanced atovaquone amorphous solid dispersion by combining a spontaneously emulsifying component with a polymer carrier. Pharmaceutics 10(2), 10078 (2018).","journal-title":"Pharmaceutics"},{"issue":"46","key":"8984_CR46","doi-asserted-by":"publisher","first-page":"465102","DOI":"10.1088\/1361-6528\/aa8c31","volume":"28","author":"SW Kim","year":"2017","unstructured":"Kim, S. W., Lee, Y. K., Yeon Lee, J., Hong, J. H. & Khang, D. PEGylated anticancer-carbon nanotubes complex targeting mitochondria of lung cancer cells. Nanotechnology 28(46), 465102 (2017).","journal-title":"Nanotechnology"},{"issue":"42","key":"8984_CR47","doi-asserted-by":"publisher","first-page":"10756","DOI":"10.1073\/pnas.1808945115","volume":"115","author":"M Benej","year":"2018","unstructured":"Benej, M. et al. Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc. Natl. Acad. Sci. U S A 115(42), 10756\u201310761 (2018).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"9","key":"8984_CR48","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1158\/2326-6066.CIR-17-0292","volume":"5","author":"RK Shrimali","year":"2017","unstructured":"Shrimali, R. K. et al. Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis. Cancer Immunol. Res. 5(9), 755\u2013766 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"8984_CR49","doi-asserted-by":"publisher","first-page":"12308","DOI":"10.1038\/ncomms12308","volume":"7","author":"TM Ashton","year":"2016","unstructured":"Ashton, T. M. et al. The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nat. Commun. 7, 12308 (2016).","journal-title":"Nat. Commun."},{"issue":"4","key":"8984_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/bjc.1955.55","volume":"9","author":"RH Thomlinson","year":"1955","unstructured":"Thomlinson, R. H. & Gray, L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 9(4), 539\u2013549 (1955).","journal-title":"Br. J. Cancer"},{"issue":"23","key":"8984_CR51","first-page":"5863","volume":"59","author":"JM Brown","year":"1999","unstructured":"Brown, J. M. The hypoxic cell: A target for selective cancer therapy\u2013eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 59(23), 5863\u20135870 (1999).","journal-title":"Cancer Res."},{"issue":"9","key":"8984_CR52","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1158\/1078-0432.CCR-20-4128","volume":"27","author":"M Skwarski","year":"2021","unstructured":"Skwarski, M. et al. Mitochondrial inhibitor atovaquone increases tumor oxygenation and inhibits hypoxic gene expression in patients with non-small cell lung cancer. Clin. Cancer Res. 27(9), 2459\u20132469 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"8984_CR53","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1172\/JCI96268","volume":"128","author":"P Jayaprakash","year":"2018","unstructured":"Jayaprakash, P. et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J. Clin. Invest. 128(11), 5137\u20135149 (2018).","journal-title":"J. Clin. Invest."},{"issue":"11","key":"8984_CR54","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nchembio.2172","volume":"12","author":"YJ Chen","year":"2016","unstructured":"Chen, Y. J. et al. Lactate metabolism is associated with mammalian mitochondria. Nat. Chem. Biol. 12(11), 937\u2013943 (2016).","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"8984_CR55","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.bbamcr.2016.03.013","volume":"1863","author":"J P\u00e9rez-Escuredo","year":"2016","unstructured":"P\u00e9rez-Escuredo, J. et al. Monocarboxylate transporters in the brain and in cancer. Biochim. Biophys. Acta 1863(10), 2481\u20132497 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"8984_CR56","unstructured":"Sidney Kimmel Cancer Center at Thomas Jefferson University, Rafael Pharmaceuticals Inc., CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer (2017). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03374852."},{"key":"8984_CR57","unstructured":"I. Calithera Biosciences, Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (2019). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03875313."},{"issue":"1","key":"8984_CR58","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12885-021-07879-5","volume":"21","author":"J Guo","year":"2021","unstructured":"Guo, J. et al. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells. BMC Cancer 21(1), 174 (2021).","journal-title":"BMC Cancer"},{"issue":"1","key":"8984_CR59","doi-asserted-by":"publisher","first-page":"ltab010","DOI":"10.1093\/immadv\/ltab010","volume":"1","author":"LJ Pallett","year":"2021","unstructured":"Pallett, L. J., Dimeloe, S., Sinclair, L. V., Byrne, A. J. & Schurich, A. A glutamine \u201ctug-of-war\u201d: Targets to manipulate glutamine metabolism for cancer immunotherapy. Immunother. Adv. 1(1), ltab010 (2021).","journal-title":"Immunother. Adv."},{"key":"8984_CR60","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3389\/fonc.2020.01342","volume":"10","author":"L Ji","year":"2020","unstructured":"Ji, L., Fan, L., Zhu, X., Gao, Y. & Wang, Z. A prognostic model for breast cancer with liver metastasis. Front. Oncol. 10, 1342 (2020).","journal-title":"Front. Oncol."},{"issue":"6","key":"8984_CR61","doi-asserted-by":"publisher","first-page":"102673","DOI":"10.1016\/j.isci.2021.102673","volume":"24","author":"G Cheng","year":"2021","unstructured":"Cheng, G. et al. Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects. iScience 24(6), 102673 (2021).","journal-title":"iScience"},{"issue":"6","key":"8984_CR62","doi-asserted-by":"publisher","first-page":"102653","DOI":"10.1016\/j.isci.2021.102653","volume":"24","author":"M AbuEid","year":"2021","unstructured":"AbuEid, M. et al. Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression. iScience 24(6), 102653 (2021).","journal-title":"iScience"},{"issue":"9","key":"8984_CR63","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1056\/NEJMcibr1914890","volume":"382","author":"RJ DeBerardinis","year":"2020","unstructured":"DeBerardinis, R. J. Tumor microenvironment, metabolism, and immunotherapy. N. Engl. J. Med. 382(9), 869\u2013871 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"8984_CR64","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1080\/14686996.2019.1590126","volume":"20","author":"K Shiraishi","year":"2019","unstructured":"Shiraishi, K. & Yokoyama, M. Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: A review. Sci. Technol. Adv. Mater. 20(1), 324\u2013336 (2019).","journal-title":"Sci. Technol. Adv. Mater."},{"issue":"3","key":"8984_CR65","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1021\/ci00063a006","volume":"29","author":"VN Viswanadhan","year":"1989","unstructured":"Viswanadhan, V. N., Ghose, A. K., Revankar, G. R. & Robins, R. K. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inform. Comput. Sci. 29(3), 163\u2013172 (1989).","journal-title":"J. Chem. Inform. Comput. Sci."},{"issue":"4","key":"8984_CR66","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1021\/ci00020a009","volume":"34","author":"G Klopman","year":"1994","unstructured":"Klopman, G., Li, J.-Y., Wang, S. & Dimayuga, M. Computer automated log P calculations based on an extended group contribution approach. J. Chem. Inf. Comput. Sci. 34(4), 752\u2013781 (1994).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"8984_CR67","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/1471-2407-13-285","volume":"13","author":"G Cheng","year":"2013","unstructured":"Cheng, G. et al. Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer 13, 285 (2013).","journal-title":"BMC Cancer"},{"issue":"1","key":"8984_CR68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1712","volume":"11","author":"SE Weinberg","year":"2015","unstructured":"Weinberg, S. E. & Chandel, N. S. Targeting mitochondria metabolism for cancer therapy. Nat. Chem. Biol. 11(1), 9\u201315 (2015).","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"8984_CR69","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nprot.2014.018","volume":"9","author":"JK Salabei","year":"2014","unstructured":"Salabei, J. K., Gibb, A. A. & Hill, B. G. Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat. Protoc. 9(2), 421\u2013438 (2014).","journal-title":"Nat. Protoc."},{"issue":"8","key":"8984_CR70","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.freeradbiomed.2010.01.028","volume":"48","author":"J Zielonka","year":"2010","unstructured":"Zielonka, J. & Kalyanaraman, B. Hydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: another inconvenient truth. Free Radical Biol. Med. 48(8), 983\u20131001 (2010).","journal-title":"Free Radical Biol. Med."},{"issue":"1","key":"8984_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2011.09.030","volume":"52","author":"B Kalyanaraman","year":"2012","unstructured":"Kalyanaraman, B. et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radical Biol. Med. 52(1), 1\u20136 (2012).","journal-title":"Free Radical Biol. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08984-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08984-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08984-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:06:07Z","timestamp":1669338367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08984-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8984"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-08984-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"22 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gang Cheng, Micael Hardy, and Balaraman Kalyanaraman are inventors of WO2021081500A1, \u201cMitochondria-targeted atovaquone: a more potent and more effective antitumor, antimicrobial, and antimalarial drug,\u201d which is under consideration by the US Patent and Trademark Office. Ming You does not have any competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5143"}}